fluconazole has been researched along with Cardiac Failure in 9 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amphotericin B was the only other antifungal that demonstrated a 2D SDR with CHF-related events." | 1.39 | A quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugs. ( Hauben, M; Hung, EY, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Broderick, KL | 1 |
| Peters, CJ | 1 |
| Mazurek, JA | 1 |
| Wald, J | 1 |
| Zhang, RS | 1 |
| Atluri, P | 1 |
| Urgo, K | 1 |
| Goldberg, L | 1 |
| Blumberg, EA | 1 |
| Weikert, BC | 1 |
| Birati, EY | 1 |
| Allen, L | 1 |
| Bartash, R | 1 |
| Minamoto, GY | 1 |
| Cowman, K | 1 |
| Patel, S | 1 |
| Vukelic, S | 1 |
| Nnani, DU | 1 |
| Fauvel, D | 1 |
| Guo, Y | 1 |
| Yazdanpanah, S | 2 |
| Ahmadi, M | 2 |
| Zare, Z | 2 |
| Nikoupour, H | 2 |
| Arabsheybani, S | 2 |
| Jabrodini, A | 2 |
| Eghtedarnejad, E | 2 |
| Chamanpara, P | 2 |
| Geramizadeh, B | 2 |
| Anbardar, MH | 2 |
| Malekizadeh, Z | 2 |
| Gashtasebi, M | 2 |
| Mohsenzadeh, M | 2 |
| Shafiekhani, M | 2 |
| Zomorodian, K | 2 |
| Siciliano, RF | 1 |
| Gualandro, DM | 1 |
| Sejas, ONE | 1 |
| Ignoto, BG | 1 |
| Caramelli, B | 1 |
| Mansur, AJ | 1 |
| Sampaio, RO | 1 |
| Pierrotti, LC | 1 |
| Barbosa, G | 1 |
| Golebiovski, W | 1 |
| Weksler, C | 1 |
| Lamas, C | 1 |
| Fortes, NRQ | 1 |
| Fortes, CQ | 1 |
| Tarasoutchi, F | 1 |
| Strabelli, TMV | 1 |
| Hauben, M | 1 |
| Hung, EY | 1 |
| Maly, J | 1 |
| Szarszoi, O | 1 |
| Netuka, I | 1 |
| Dorazilova, Z | 1 |
| Pirk, J | 1 |
| Gamma, R | 1 |
| Carrel, T | 1 |
| Schmidli, J | 1 |
| Zimmerli, S | 1 |
| Tanner, H | 1 |
| Hullin, R | 1 |
| Mohacsi, PJ | 1 |
| du Plessis, FA | 1 |
| Helbing, WA | 1 |
| Bogers, AJ | 1 |
| Saito, Y | 1 |
| Takahashi, M | 1 |
| Sato, A | 1 |
| Katsuki, T | 1 |
| Ikeda, U | 1 |
| Shimada, K | 1 |
1 review available for fluconazole and Cardiac Failure
| Article | Year |
|---|---|
Fungal infections associated with long-term mechanical circulatory support-diagnosis and management.
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Fluconazole; Heart Failure; Heart-Assist Devices; Hum | 2014 |
8 other studies available for fluconazole and Cardiac Failure
| Article | Year |
|---|---|
Characteristics and Outcomes of Candidemia in Patients with Durable Left Ventricular Assist Device Support.
Topics: Candidemia; Diabetes Mellitus; Fluconazole; Heart Failure; Heart-Assist Devices; Humans; Retrospecti | 2022 |
Impact of narrowing perioperative antibiotic prophylaxis for left ventricular assist device implantation.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Cefazolin; Ciprofloxacin; Fluconazole; Heart Failure; | 2022 |
Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Coinfection; COVID-19; Drug Resistance, F | 2023 |
Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Coinfection; COVID-19; Drug Resistance, F | 2023 |
Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Coinfection; COVID-19; Drug Resistance, F | 2023 |
Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Coinfection; COVID-19; Drug Resistance, F | 2023 |
Outcomes in patients with fungal endocarditis: A multicenter observational cohort study.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida; Echinocandins; Endocarditis; Female; Fluconazole; | 2018 |
A quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugs.
Topics: Adverse Drug Reaction Reporting Systems; Amphotericin B; Antifungal Agents; Databases, Factual; Drug | 2013 |
Transplantation of yeast-infected cardiac allografts: a report of 2 cases.
Topics: Adult; Amphotericin B; Candida albicans; Candidiasis; Fluconazole; Follow-Up Studies; Graft Survival | 2005 |
Excision of the tricuspid valve in a baby with Candida endocarditis.
Topics: Antifungal Agents; Candidiasis; Endocarditis; Female; Fluconazole; Heart Failure; Humans; Infant; Ni | 2007 |
Isolated tricuspid valve endocarditis due to Candida parapsilosis associated with long-term central venous catheter implantation.
Topics: Aged; Amphotericin B; Antifungal Agents; Candidiasis; Catheterization, Central Venous; Echocardiogra | 2001 |